title: Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop.
abstract: This report represents a further update of the consensus panel criteria for the assessment of clinical response in patients with Waldenström macroglobulinaemia (WM). These criteria have been updated in light of further data demonstrating an improvement in categorical responses with new drug regimens as well as acknowledgement of the fact that such responses are predictive of overall outcome. A number of key changes are proposed but challenges do however remain and these include the variability in kinetics of immunoglobulin M (IgM) reduction with different treatment modalities and the apparent discrepancy between IgM and bone marrow/tissue response noted with some regimens. Planned sequential bone marrow assessments are encouraged in clinical trials.
authors.affiliation: St James's University Hospital, Leeds, UK. rogerowen@nhs.net
authors.forename: Roger G
authors.initials: RG
authors.lastname: Owen
authors.forename: Robert A
authors.initials: RA
authors.lastname: Kyle
authors.forename: Marvin J
authors.initials: MJ
authors.lastname: Stone
authors.forename: Andy C
authors.initials: AC
authors.lastname: Rawstron
authors.forename: Veronique
authors.initials: V
authors.lastname: Leblond
authors.forename: Giampaolo
authors.initials: G
authors.lastname: Merlini
authors.forename: Ramon
authors.initials: R
authors.lastname: Garcia-Sanz
authors.forename: Enrique M
authors.initials: EM
authors.lastname: Ocio
authors.forename: Enrica
authors.initials: E
authors.lastname: Morra
authors.forename: Pierre
authors.initials: P
authors.lastname: Morel
authors.forename: Kenneth C
authors.initials: KC
authors.lastname: Anderson
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Patterson
authors.forename: Nikhil C
authors.initials: NC
authors.lastname: Munshi
authors.forename: Alessandra
authors.initials: A
authors.lastname: Tedeschi
authors.forename: Douglas E
authors.initials: DE
authors.lastname: Joshua
authors.forename: Efstathios
authors.initials: E
authors.lastname: Kastritis
authors.forename: Evangelos
authors.initials: E
authors.lastname: Terpos
authors.forename: Irene M
authors.initials: IM
authors.lastname: Ghobrial
authors.forename: Xavier
authors.initials: X
authors.lastname: Leleu
authors.forename: Morie A
authors.initials: MA
authors.lastname: Gertz
authors.forename: Stephen M
authors.initials: SM
authors.lastname: Ansell
authors.forename: William G
authors.initials: WG
authors.lastname: Morice
authors.forename: Eva
authors.initials: E
authors.lastname: Kimby
authors.forename: Steven P
authors.initials: SP
authors.lastname: Treon
mesh_terms: D000911:Antibodies, Monoclonal / Q000097:blood / Q000627:therapeutic use; D000963:Antimetabolites / Q000627:therapeutic use; D001856:Bone Marrow Examination / Q000379:methods / Q000592:standards; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D003720:Densitometry; D018450:Disease Progression; D018572:Disease-Free Survival; D005544:Forecasting; D006410:Hematopoiesis; D006801:Humans; D007147:Immunoglobulin Light Chains / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D018365:Neoplasm, Residual; D009391:Nephelometry and Turbidimetry; D049268:Positron-Emission Tomography; D011719:Pyrazines / Q000627:therapeutic use; D012074:Remission Induction; D016019:Survival Analysis; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D008258:Waldenstrom Macroglobulinemia / Q000097:blood / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D000963:Antimetabolites; D001897:Boronic Acids; D007147:Immunoglobulin Light Chains; D007075:Immunoglobulin M; D007166:Immunosuppressive Agents; D011719:Pyrazines; D000069286:Bortezomib